• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of xcience and technology policy >5 The Circumstances Affecting Incentives for the Development of Drug-Eluting Stents
【24h】

5 The Circumstances Affecting Incentives for the Development of Drug-Eluting Stents

机译：5的情况下影响激励药物洗脱支架的发展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To illustrate the foregoing ideas and to discuss them in the context of an important biomedical innovation that received substantial public funding from both of the two avenues that we have discussed in Section 2, we shall consider the details about the R&D competitors in the development of drug-eluting coronary stents, our main example. We want to describe the correspondence between the R&D competition in the biomedical industry, as illustrated with the situation for drug-eluting stents, and the set of circumstances where that competition can make government royalties and appropriate incentives compatible. The essential question to be addressed is whether Figure 4.2 reasonably describes the situation for biomedical R&D. In fact, Scherer (2010, pp. 564-569) makes the argument that the answer is yes for the development of new pharmaceutical/medical products.
机译：为了说明上述观点和讨论他们中一个重要的生物医学创新,收到大量的公众资金从两个途径在第二节所讨论的,我们应当考虑的研发竞争对手的详细信息药物洗脱冠状动脉支架的发展,我们的主要的例子。研发竞争之间的通信生物医药行业,如所描述的药物洗脱支架的情况下,一组情况下,竞争政府版税和适当的激励兼容的。图4.2是否合理解决描述了生物医学研发的情况。事实上,谢勒(2010年,第569 - 564页)认为答案是肯定的新的制药/医疗的发展产品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号